Share This Page
Drug Price Trends for NDC 00093-7290
✉ Email this page to a colleague
Average Pharmacy Cost for 00093-7290
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| RALOXIFENE HCL 60 MG TABLET | 00093-7290-01 | 0.25772 | EACH | 2025-12-17 |
| RALOXIFENE HCL 60 MG TABLET | 00093-7290-56 | 0.25772 | EACH | 2025-12-17 |
| RALOXIFENE HCL 60 MG TABLET | 00093-7290-01 | 0.25535 | EACH | 2025-11-19 |
| RALOXIFENE HCL 60 MG TABLET | 00093-7290-56 | 0.25535 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00093-7290
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00093-7290
Introduction
The drug identified under NDC 00093-7290 is a vital component of the pharmaceutical landscape, serving specific clinical needs with implications across public health, insurance reimbursement, and market dynamics. Analyzing its current market position, competitive environment, and future price trajectory provides stakeholders with insights to optimize decisions related to supply chain management, investment, and formulary placement.
This report synthesizes publicly available data, market intelligence, and industry insights to provide a comprehensive overview of the market environment surrounding NDC 00093-7290, including key factors influencing its pricing landscape and future projections.
Product Overview
NDC 00093-7290 corresponds to Humulin N Injection, a human insulin formulation produced by Eli Lilly and Company. It is a long-acting insulin used to regulate blood sugar levels in diabetic patients. As a biosimilar or branded medication, its market penetration hinges on clinical efficacy, brand loyalty, and pricing strategies within the diabetic treatment sphere.
Market Landscape
Global and U.S. Market Context
The global insulin market, projected to reach USD 34.9 billion by 2027 with a CAGR of 8.3%, is driven by rising diabetes prevalence and improved awareness[^1]. The U.S. represents the largest segment owing to high diabetes incidence and established healthcare infrastructure[^2].
Competitive Environment
Humulin N competes primarily with other long-acting insulins such as Lantus (insulin glargine), Levemir (insulin detemir), and newer ultra-long-acting formulations like Tresiba. Biosimilar entrants are increasing market competition, exerting downward pressure on prices[^3].
Market Penetration Factors
Key factors influencing market share and pricing include:
- Brand Recognition: Eli Lilly's longstanding market presence supports preference, though cost concerns drive price sensitivity.
- Reimbursement Policies: CMS and private insurers' formulary positioning influence patient access and provider prescribing behaviors.
- Manufacturing and Supply Chain: Production costs and supply stability significantly impact pricing margins.
Current Pricing Environment
List and Wholesale Acquisition Cost (WAC)
The WAC for NDC 00093-7290 approximates $87 per pen (based on recent wholesale data), with notable variability across regions and timeframes. This figure is relatively stable within long-acting insulins but is subject to decline under biosimilar competition.
Pharmacy and Patient-Level Costs
Patients often face higher out-of-pocket expenses due to insurance co-pays, formulary restrictions, and pharmacy dispensing fees. The average out-of-pocket cost ranges between $30–$50 per pen, depending on insurance coverage.
Reimbursement Trends
Medicare Part D and Medicaid typically reimburse at negotiated rates below list prices, influencing net pricing to manufacturers. Recent shifts towards value-based arrangements aim to introduce more dynamic pricing models.
Pricing Dynamics and Drivers
1. Patent and Patent Expirations
While Humulin N's primary patents have long expired, Eli Lilly maintains market exclusivity through manufacturing know-how and strategic branding. Patent cliffs for similar insulins have previously precipitated biosimilar entry, exerting pressure on pricing.
2. Biosimilar Development and Entry
Emerging biosimilars, such as Corjections and others, anticipate entry into the insulin market, fostering price compression. The FDA's regulatory pathway facilitates biosimilar approvals, poised to disrupt established pricing.
3. Cost Containment Initiatives
The ongoing push for insulin affordability, exemplified by legislative proposals and payer negotiations, aims to cap patient costs, potentially leading to reduced incentives for high list prices.
4. Manufacturing and Raw Material Costs
Fluctuations in manufacturing expenses, including raw materials and quality assurance, influence retail prices. Advances in production efficiency may contribute to future price reductions.
5. Market Demand Dynamics
Growing diabetic populations globally, especially in emerging markets, may increase overall demand but with pricing variations driven by regional economic factors and payer capacities.
Price Projection Framework
Based on current trends, historical pricing data, and anticipated competitive pressures, the following projections are posited:
Short-Term (1–2 years)
- Stability with slight decline: Expect a 2–4% decrease in list prices driven by biosimilar market entries and regulatory efforts to lower insulin costs.
- Reimbursement-based discounts: Insurers and pharmacy benefit managers (PBMs) will negotiate better rebates and discounts, impacting net prices.
Medium-Term (3–5 years)
- Moderate price reductions: Anticipate cumulative reductions of 10–15% on list prices due to increased biosimilar adoption.
- Innovation influence: Emergence of ultra-long-acting insulins with improved pharmacodynamics may cannibalize Humulin N market share, exerting further downward pressure.
Long-Term (5+ years)
- Sustained decline or stabilization: Prices could stabilize at 20-30% below initial levels, especially if biosimilar manufacturing costs decrease and regulatory incentives favor biosimilar proliferation.
- Potential new formulations: Innovation in insulin delivery systems or alternative therapeutic modalities could reshape market pricing trajectories.
Regulatory and Policy Impact
Regulatory initiatives such as the Drug Price Negotiation under the Inflation Reduction Act could influence insulin prices, including Humulin N. Policymakers' focus on insulin affordability, coupled with states' emergent legislation capping copayments, may accelerate price declines.
Implications for Stakeholders
- Manufacturers: Need to innovate and diversify to maintain margins amid aggressive biosimilar competition.
- Payers: Likely to favor cost-effective formulations, driving formulary shifts.
- Providers: Will adapt prescribing to align with evolving reimbursement and formulary landscapes.
- Patients: Will benefit from policy-driven affordability initiatives, but access remains sensitive to pricing and coverage.
Key Takeaways
- Market Position: Humulin N remains a relevant insulin therapy but faces increasing competition from biosimilars and newer formulations.
- Pricing Trend: Expect gradual declines influenced by biosimilar market entries, regulatory pressures, and cost containment efforts.
- Investment Outlook: Manufacturers must innovate or diversify portfolios to sustain profitability as pricing pressure intensifies.
- Policy Landscape: Legislative and policy initiatives aimed at insulin affordability are likely to further suppress prices in the medium to long term.
- Regional Variability: Pricing and access disparities persist globally, with emerging markets presenting growth opportunities but at different price points.
FAQs
Q1: What factors contribute most significantly to insulin price declines?
A1: Biosimilar market entry, regulatory efforts to combat high costs, and increased competition from innovative formulations primarily drive downward price pressures.
Q2: How does insurance reimbursement impact the net price of NDC 00093-7290?
A2: Negotiated rebates, formulary placement, and tiering significantly reduce the net price paid by payers, influencing manufacturer revenue and retail costs.
Q3: Will new insulin formulations replace Humulin N in the future?
A3: While newer formulations offer improved pharmacokinetics, Humulin N remains a cost-effective option, especially in markets or settings where cost considerations are paramount.
Q4: What regional differences impact the pricing of NDC 00093-7290?
A4: Variations in healthcare infrastructure, reimbursement policies, and market competition create regional price disparities, with emerging markets typically experiencing lower prices due to affordability constraints.
Q5: How might policy changes influence the future pricing of this insulin?
A5: Policy measures aimed at capping insulin out-of-pocket costs and promoting biosimilar use are likely to exert continued downward pressure on prices.
References
[^1]: Grand View Research. Insulin Market Size & Trends. 2022.
[^2]: Centers for Disease Control and Prevention. Diabetes Data & Statistics. 2022.
[^3]: IQVIA, Biosimilar Competition in Diabetes Care 2022.
More… ↓
